Resverlogix raises $50 mln in funding from Hepalink, Eastern Capital
Resverlogix Corp (TSX: RVX) has completed a private placement transaction, raising $50 million in proceeds. The funding came from Chinese strategic investor Shenzhen Hepalink Pharmaceutical Co Ltd and Eastern Capital, a Cayman Islands life sciences investor. As a result of the deal, Hepalink holds about 12.63 percent of the company's common shares, while Eastern holds about 19.57 percent. Based in Calgary, Resverlogix is a developer of treatments for patients with cardiovascular disease and other conditions. It is also a portfolio investment of U.S. venture capital firm NGN Capital.
21 July 2015•2 mins read
